Brainstorm Cell Therapeutics : Letter To Shareholders

Alert to Shareholders

Dear Shareholders,

We are so happy that Brainstorm's Phase 3 clinical trial is finally getting noticed by the national press and within the last few days we were featured on various prestigious news outlets across the U.S. We had no control of the timing of these stories which aired during the Passover Holiday and Sabbath (Saturday) but we want to make sure that you have an opportunity to view them. So, we are happy to share with you the following information and links to the featured stories about our ongoing Phase 3 NurOwn trial for ALS.

CBS News aired a story nationally based on an interview with an ALS patient being treated at Mass General Hospital / Harvard in Boston (click here to view:https://goo.gl/i3vmZE). Our Principal Investigator at MGH, Dr. Merit Cudkowicz, was interviewed as part of this. The story was also featured on CBSNEWS.com as well as WBZ (CBS Boston) (click here to view:https://goo.gl/NzA4Lq) and many local affiliates.

KABC, ABC's local TV station in Los Angeles, featured an interview with an ALS patient enrolled in the trial at UC Irvine (click here to view:https://goo.gl/Xw4fKd). They also interviewed Dr. Namita Goyal who serves as Brainstorm's Principal Investigator at UCI.

The Boston Globe featured a front page story based on an interview with another ALS patient being treated at MGH (click here to view:https://goo.gl/9G78Po). They also interviewed, among others, Drs. Merit Cudkowicz, Robert Brown and Robert Miller who are Principal Investigators at MGH, U. Mass and CPMC in San Francisco, respectively

Channel 5 News from Arizona interviewed a local patient from Arizona being treated at U Mass (click here to view:https://goo.gl/gXbwFo).

We appreciate that these patients agreed to be interviewed and would like to express our gratitude to all the patients and physicians that are participating in this important trial.

Chaim Lebovits

President & CEO

BrainStorm Cell Therapeutics Inc.